Definitions in Hemophilia: Resolved and Unresolved Issues

Abstract Definitions of clinical events and end points of care are important for disease characterization as well as documentation of outcomes in clinical practice and trials. Until recently, the only definitions in hemophilia that were provided through an international scientific organization related to disease severity and levels of inhibitors. Recently, the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis, through its Factor VIII and IX subcommittee, published consensus definitions for several other aspects of hemophilia management, including classification of disease severity; inhibitors; bleeding (and rebleeding) into muscles and joints; target joints; different forms of factor replacement therapy; and response to therapy for joint bleeding and surgical hemostasis. These definitions should help to bring greater uniformity in the documentation of critical clinical events and laboratory data that are reported both from clinical trials as well as real-world practice. This article describes these definitions in greater detail than the SSC short report and also addresses some of the unresolved issues. Wide dissemination of these concepts and definitions and their acceptance by relevant leading scientific societies, drug regulators, industry, and patient organizations will go a long way in ensuring their acceptance and use globally.

[1]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[2]  V. Blanchette,et al.  Assessment of outcomes , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  R. Liesner,et al.  Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) , 2013, British journal of haematology.

[5]  P. Babyn,et al.  Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada , 2012, Journal of Thrombosis and Haemostasis.

[6]  T. Lambert,et al.  Tertiary prophylaxis in adults: is there a rationale? , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  C. Miller,et al.  Validation of Nijmegen–Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance , 2012, Journal of thrombosis and haemostasis : JTH.

[8]  J. Oldenburg,et al.  Low‐titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half‐life after immune tolerance induction , 2012, Journal of thrombosis and haemostasis : JTH.

[9]  D. Grobbee,et al.  Clinical severity of haemophilia A: does the classification of the 1950s still stand? , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  B. Verbruggen,et al.  The between-Laboratory Variation of Factor VIII Inhibitor Testing: The Experience of the External Quality Assessment Program of the ECAT Foundation , 2009, Seminars in thrombosis and hemostasis.

[11]  A. Iorio,et al.  Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. , 2009, Blood.

[12]  V. Blanchette,et al.  Definitions for haemophilia prophylaxis and its outcomes: The Canadian Consensus Study , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  M. Makris,et al.  Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors , 2006, Thrombosis and Haemostasis.

[14]  S. Donadel-Claeyssens Current co‐ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management) , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  V. Blanchette,et al.  A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  J. Astermark,et al.  Consensus perspectives on prophylactic therapy for haemophilia: summary statement , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  D. Grobbee,et al.  The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. , 2002, Blood.

[18]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[19]  J. Astermark,et al.  Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized , 1999, British journal of haematology.

[20]  M. Power,et al.  Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment , 1998, Psychological Medicine.

[21]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[22]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[23]  E. Berntorp,et al.  Pharmacokinetics of Factor VIII in Humans , 1992, Clinical pharmacokinetics.

[24]  R. G. Macfarlane,et al.  Haemophilia and Related Conditions: A Survey of 187 Cases , 1958, British journal of haematology.

[25]  B. O’Mahony An introduction to key concepts in health economics for haemophilia organisations , 2011 .

[26]  J. Stockman Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .

[27]  Eric F. Gardner,et al.  Summary Statement , 1946 .